xIPOmeter
Tempus
Tempus is an American biotechnology company that provides data and AI services for the healthcare industry. The company collects genomic data from patients, organizes it, and provides insights with the help of machine learning. It has 3.5+ million patient records in its oncology dataset. Tempus' products and services are used in oncology, neurology, life sciences and infectious disease research to provide patients with personalized, targeted therapies.
Tempus offers services both directly to patients and through physicians. The company is headquartered in Chicago, Illinois.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
News related to Tempus161
TempusTempus to Report Second Quarter 2024 Financial Results on August 6 - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings confere...
Tempushttps://www.tempus.com/news/tempus-to-report-second-quarter-2024-financial-results-on-august-6/TempusTempus Expands Immuno-Oncology Portfolio with Launch of AI-enabled, Multimodal Immune Profile Algorithmic Tests - Tempus
Available Today for Life Science Research Use Only Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use...
Tempushttps://www.tempus.com/news/tempus-expands-immuno-oncology-portfolio-with-launch-of-ai-enabled-multimodal-immune-profile-algorithmic-tests/TempusTempus Surpasses 500 Research Publications - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has reached a research milestone of over 500 research publications. In the last eight years, Tempus has invested in rigorous scientific research to validate its dia...
Tempushttps://www.tempus.com/news/tempus-surpasses-500-research-publications/TempusTempus Announces Sequencing and Computational Biology Collaboration with Kronos Bio to Support the Development of CDK9 Inhibitor KB-0742 - Tempus
Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigatio...
Tempushttps://www.tempus.com/news/pr/tempus-announces-sequencing-and-computational-biology-collaboration-with-kronos-bio-to-support-the-development-of-cdk9-inhibitor-kb-0742/TempusCMS Awards Tempus With Advanced Diagnostic Laboratory Test (ADLT) Status for its xT CDx Test - Tempus
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Advanced Diagnostic Laboratory Test (ADLT) status for Tempus’ next-generation se...
Tempushttps://www.tempus.com/news/cms-awards-tempus-with-advanced-diagnostic-laboratory-test-adlt-status-for-its-xt-cdx-test/
Show more (156)Investors8
New Enterprise Associates
Revolution
T. Rowe Price
Baillie Gifford
Novo Holdings
Franklin Templeton
Google
Franklin Templeton Investments